
S&P/ASX 200 Index (ASX: XJO) shares are 0.2% higher at 8,714.9 points on Thursday.
Meanwhile, brokers have lifted their ratings on several ASX 200 shares this week.Â
Let’s review.
CSL Ltd (ASX: CSL)
The CSL share price is $177.29, up 1.7% today.
Over the past month, this ASX 200 healthcare share has ripped 32%.
RBC Capital upgraded CSL shares to a buy rating on Tuesday.
The broker raised its 12-month price target substantially from $148 to $213.
This implies a potential 20% upside ahead.
National Australia Bank Ltd (ASX: NAB)
The NAB share price is $38.91, up 2.3% today.
Over the past month, this ASX 200 bank share has fallen 1%.
Citi upgraded NAB shares to a buy rating yesterday.
The broker increased its 12-month price target from $40 to $42.10.
This suggests a potential 8% upside ahead.
Lottery Corporation Ltd (ASX: TLC)
The Lottery Corporation share price is $4.86, up 0.7% today.
Over the past month, this ASX 200 consumer discretionary share has fallen 9%.
Morgans upgraded Lottery Corporation shares to a buy call today.
The broker reduced its 12-month price target from $5.60 to $5.40.
This implies a potential 11% upside ahead.
Ramsay Health Care Ltd (ASX: RHC)
The Ramsay Health Care share price is $55.06, up 0.4% today.
Over the past month, this ASX 200 healthcare share has risen 23%.
RBC Capital upgraded Ramsay Health Care shares to a buy call this week.
The broker increased its 12-month price target significantly from $52 to $68.
This indicates potential capital gains of 23% over the next year.Â
Challenger Ltd (ASX: CGF)
The Challenger share price is $10.09, down 1.9% today.
Over the past month, this ASX 200 financial share has increased 4%.
UBS upgraded Challenger shares to a buy rating with a $11.50 price target.
This suggests a potential 14% upside ahead.
James Hardie Industries Plc (ASX: JHX)
The James Hardie share price is $37.38, up 0.2% today.
Over the past month, this ASX 200 materials share has fallen 15%.
Morgans upgraded James Hardie shares to an accumulate rating yesterday.
The broker shaved its 12-month price target from $45 to $43.
This suggests potential capital growth of 15% over the next year.
Morgans said:
The positive company story and the growth trajectory are only partially offset by the tough macro, a 75bps rise in the 30-year mortgage rate over the past six months, and a peer multiple de-rate.
On this basis we upgrade to an Accumulate rating, whilst moderating our target price to A$43.00 (from A$45.00).
The post 6 ASX 200 shares boosted by brokers this week appeared first on The Motley Fool Australia.
Should you invest $1,000 in Challenger right now?
Before you buy Challenger shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Challenger wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 August 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Forget CSL shares, I’d buy this ASX biotech stock instead
- James Hardie says it doesn’t need a US housing recovery. Can it prove it?
- CSL acknowledges “disappointing” results but aims to do better
- CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded
- Santos, Ramsay Health Care, and AMP shares reach new 52-week highs: Can they keep climbing?
Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and The Lottery Corporation. The Motley Fool Australia has recommended CSL, Challenger, and The Lottery Corporation. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

